PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer.
| Author | |
|---|---|
| Abstract |
:
Trastuzumab is an active agent against human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC). This study aimed to characterize resistance to trastuzumab-based front-line chemotherapy in HER2+ GC patients and to establish factors predictive of this resistance. |
| Year of Publication |
:
2017
|
| Journal |
:
Oncotarget
|
| Volume |
:
8
|
| Issue |
:
69
|
| Number of Pages |
:
113494-113501
|
| Date Published |
:
2017
|
| DOI |
:
10.18632/oncotarget.23054
|
| Short Title |
:
Oncotarget
|
| Download citation |
